期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

急性冠状动脉综合征伴慢性肾脏病患者介入术后抗血小板药物抵抗研究 被引量：4

Antiplatelet drugs resistance after percutaneous coronary intervention in patients with acute coronary syndrome and chronic kidney disease
原文传递
导出
摘要 目的:探讨急性冠状动脉综合征(ACS)伴慢性肾脏病(CKD)的患者经皮冠状动脉介入术后氯吡格雷和阿司匹林抵抗的发生情况。方法:将133例ACS患者根据肾功能情况分为3组:肾功能正常组(66例),轻度CKD组(50例),中重度CKD组(17例)。通过血栓弹力图检测比较3组患者服用氯吡格雷和阿司匹林后的血小板抑制率。结果:肾功能正常组,轻度CKD组与中重度CKD组抗血小板药物抵抗发生率分别为25.8%、44.0%和52.9%,后两组比较差异无统计学意义(P=0.532),但都明显高于肾功能正常组(P<0.05)。结论:伴CKD的ACS患者更易出现抗血小板药物抵抗,采用个性化抗血小板治疗,可以减少临床缺血事件的发生。 Objective：To investigate the resistance of clopidogrel and aspirin in patients with acute coronary syndrome （ACS） complicated with chronic kidney disease （CKD） underwent percutaneous coronary intervention. Method：According to renal function in ACS patients, 133 cases were divided into 3 groups： normal renal function （n= 66）, mild CKD （n=50）, moderate/severe CKD （n= 17）. By thromboelastography tests, resistance of plate- let was compared among three groups of patients intaking clopidogrel and aspirin. Result： The anti-platelet drug resistance rate in normal renal function group, mild CKD group and moderate/severe CKD group were 25.8%, 44.0% and 52.9%, respectively. The resistance incidence of clopidogre[ and aspirin in patients with renal dys- function was significantly higher than the patients with normal renal function （P〈0.05）. The incidence of resist- ance to antiplatelet drugs did not show any difference in mild CKD and moderate/severe CKD groups （P= 0. 532）. Conclusion：The patients with ACS and CKD are more vulnerable to form anti-platelet drug resistance. Individualized antiplatelet therapy can reduce the resistance cidence against antiplatelet dugs.
作者 陈娜 季汉华
机构地区 北京大学民航总医院心内科
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2012年第10期750-754,共5页 Journal of Clinical Cardiology
关键词 冠状动脉综合征 急性 慢性肾脏病 氯吡格雷抵抗 阿司匹林抵抗 血小板聚集率 coronary syndrome, acute chronic kidney disease clopidogrel resistance aspirin resistance platelet aggregation
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献21

  • 1HAGE F G, VENKATARAMAN R, ZOGHBI G, et al. The scope of coronary heart disease in patients with chronic kidney disease[J]. J Am Coll Cardiol. 2009,53:2129-2140.
  • 2MUNTNER P, HE J, HAMM L. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States[J]. J Am Soc Nephrol. 2002,13:745-753.
  • 3LAMBERT N D, SACRINTY M T, KETCH T R. et al. Chronic kidney disease and dipstick protcinuria arerisk factors for stent thrombosis in pavients with myocar dial infarction[J]. Am Heart J.2009.157:688 -691.
  • 4ZHU Z B, ZHANG R Y, ZHANG Q. et al. Moderate-severe renal insufficiency is a risk factorr for sirolimus-eluting stent thrombosis. The RIFT study J .Cardiology, 2009 112:191-199.
  • 5LATIF F, KI.EIMAN N S, COHEN D J, et al. Inhospital and 1-year outcomes among percutaneous cor- onary intervention patients with chronic kidney disease in the era of drug-elnting stents: a report from the E- VENT (Evaluation of Drug Eluting Stents and lschemic Events) registry[J]. J Am Coll Cardiot Inlv. 2009,2.37-45.
  • 6BEST P J, LENNON R, TING H It, et al. The im- pact of renal insufficiency on clinical outcomes in nai tients undergoing pereutaneous coronary intervemins[J]. J AmCollCardiol,2002,33:1113-1119.
  • 7BEST P J, STEINHUBL S R, BERGER P B. et al. The efficacy and safety of short and long-term dual anti- platelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Re duetion of Events During Observation (CRF.1)()) trial [J]. Am HeartJ,2008,155:687-693.
  • 8DASGUP'FA A, STEINHUBI. S R, BHATT D I, et al. Clinical outcomes of patients with diabelie nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the Clopidogrel for High Atherothrombotic Risk and lschemic Stabilization, Management,and Avoidance ECHARISMAd trial)[J]. AmJCardiol,2009,103:1359-1363.
  • 9TANTRY U S, BLIDEN K P, GURBEL P A. Overestimation of platelet aspirin resistance detection by throm- belastograph platelet mapping ad validation hy conventional aggregometry using arachidonic acid stimulation [J]. JArn Coll Cardiol, 2005,46 : 1705 - 1709.
  • 10GEISLER T, SCHAEFFEI.ER E, DIPPON J, et al. CYP2C19 and nongenetic factors predict poor responsiveness to ctopidogrel loading dose after coronary stent implantation[J]. Pharmacogenomics, 2008,9 : 1251 -- 1259.

二级参考文献6

  • 1GOLDBERG A, HAMMERMAN H, PETCHERSKI S, et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction[J]. Am Heart J, 2005, 150:330--337.
  • 2LATCHAMSETTY R, FANG J, KLINE-ROGERS E, et al. Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndrome[J].Am J Cardiol, 2007, 99:939--942.
  • 3RIHAL C S, TEXTOR S C, GRILL D E, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention[J].Circulation, 2002, 105:2259-2264.
  • 4COWIE M R, KOMAJDA M, MURRAY-THOMAS T, et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure., results of the prospective outcomes study in heart failure (POSH) [J]. Eur Heart J, 2006, 27:1216--1222.
  • 5EFENDIGIL M C, HARLEY A, DEEGAN T, et al. Changes in glomerular filtration rate following myocardial infarction[J]. Cardiovasc Res, 1975, 9 : 741 - 744.
  • 6HILLEGE H L, VAN GILST W H, VAN VELDHUISEN D J, et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial[J].Eur Heart J, 2003, 24:412--420.

共引文献9

同被引文献21

  • 1杨超,李彦,杨永忠.磺达肝癸钠对非ST段抬高急性冠脉综合征的疗效与安全性的研究[J].药物与临床,2013,10(3):91-95.
  • 2Tantry US,Bliden KP, Gurbel PA.Overestimation of platelet aspirin resistan ce detection by thrombelastograph platelet mapping advalidation by conv entional aggregometry using arachidonic acid stimulation[J]. Am Coll Car diol,2005,46(9):1 705-1 709.
  • 3Alexander GG.Turpie. Selective factor X a inhibition with fondaparinux: from concept to clinical benefit [J].Eur Heart J Suppl,2008,10(Suppl C): C1-C7.
  • 4Savi RChong BH,Greinacher A,et al.Effect of fondaparinux on platelet act ivation in the presence of heparin-dependent antibodies: a blinded compar ative multicenter study with unfractionated heparin[J].Blood,2005,105(1): 139-144.
  • 5Bauersachs RM.Fondaparinux: an update on new study results[J].Eur J Clin Invest,2005,35(1):27-32.
  • 6ACC/AHA UA/NSTEEMI Guideline Revision Anderson JL,et al.Circulati on.2007,50(7):e 1-e 157.
  • 7Yusuf S,Mehta SR,Chrolavicius S,et al.Comparison of fondaparinux and enoxaparin in acute coronary syndromes[J].N Engl J Med,2006,354(14):l 464-1 476.
  • 8Paul AG,Samara WM,Bliden KP.Failure of clopidogrel to reduce platelet re activity and activation following standard doing in elective stenting:imp li cations for thrombotic events and restenosis[J]. Platelets,2004,15(2):95-99.
  • 9Wenaweser P, Dorffler MJ,lmboden K,et al.Stent thrombosis is associa ted with an impaired response to antiplatelet therapy[J].J Am Coil Cardi ol,2005,45(11): 1 748-1 752.
  • 10Mega JL, Braunwald E, Wiviott SD, et al . Rivaroxaban in patients with a recent acute coronary syndrome[J]. N Engl J Med, 2012, 366(1): 9-19.

引证文献4

二级引证文献17

临床心血管病杂志
2012年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部